Search

Your search keyword '"Dery, Jean-Pierre"' showing total 77 results
Start Over Author "Dery, Jean-Pierre"
77 results on '"Dery, Jean-Pierre"'

51. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes

Author

Smyth, Susan S., primary, Moliterno, David J., primary, Rorick, Tyrus L., primary, Moccetti, Tiziano, primary, Valgimigli, Marco, primary, Dery, Jean Pierre, primary, Cornel, Jan H., primary, Thomas, Gregory S., primary, Huber, Kurt, primary, Harrington, Robert A., primary, Hord, Edward, primary, Judge, Heather M., primary, Chen, Edmond, primary, Strony, John, primary, Mahaffey, Kenneth W., primary, Tricoci, Pierluigi, primary, Becker, Richard C., primary, Storey, Robert F., additional, Kotha, Jayaprakash, additional, and Jennings, Lisa K., additional

Published
2014
Full Text
View/download PDF

52. Arterial Access Site and Outcomes in Patients Undergoing Percutaneous Coronary Intervention With and Without Vorapaxar

Author

Dery, Jean-Pierre P., Mahaffey, Kenneth, Tricoci, Pierluigi, White, Harvey, Podder, Mohua, Moliterno, David, Harrington, Robert, Chen, Edmond, Strony, John, Van de Werf, Frans, Ziada, Khaled M., Held, Claes, Aylward, Philip, Armstrong, Paul W., Rao, Sunil, Dery, Jean-Pierre P., Mahaffey, Kenneth, Tricoci, Pierluigi, White, Harvey, Podder, Mohua, Moliterno, David, Harrington, Robert, Chen, Edmond, Strony, John, Van de Werf, Frans, Ziada, Khaled M., Held, Claes, Aylward, Philip, Armstrong, Paul W., and Rao, Sunil

Published
2013

53. PHARMACODYNAMICS OF VORAPAXAR, A PLATELET PAR-1 ANTAGONIST, AND ITS INTERACTION WITH P2Y12 RECEPTOR PATHWAY IN THE TRACER TRIAL

Author

Jennings, Lisa K., primary, Moliterno, David, additional, Storey, Robert, additional, Hord, Edward, additional, Kotha, Jayaprakash, additional, Becker, Richard, additional, Smyth, Susan, additional, Providencia, Luis, additional, Moccetti, Tiziano, additional, Valgimigli, Marco, additional, Dery, Jean-Pierre, additional, Cornel, J.H., additional, Thomas, Gregory, additional, Huber, Kurt, additional, Chen, Edmond, additional, Strony, John, additional, Rorick, Tyrus, additional, Tricoci, Pierluigi, additional, and Mahaffey, Kenneth, additional

Published
2012
Full Text
View/download PDF

54. ADEQUATE SCREENING CAN REDUCE RADIAL ACCESS FAILURE RATES IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS UNDERGOING PRIMARY PERCUTANEOUS CORONARY INTERVENTION

Author

Dery, Jean-Pierre, primary, Bouchard, Marie-Pier, additional, Dery, Ugo, additional, Roy, Melanie, additional, Rodes-Cabau, Josep, additional, Rinfret, Stephane, additional, Larose, Eric, additional, Barbeau, Gerald, additional, Rouleau, Jacques, additional, Roy, Louis, additional, Noel, Bernard, additional, nguyen, can, additional, Gleeton, Onil, additional, Proulx, Guy, additional, Boudreault, Jean-Rock, additional, De La Rochellière, Robert, additional, Rao, Sunil, additional, and Bertrand, Olivier, additional

Published
2012
Full Text
View/download PDF

55. Effectiveness and safety of glycoprotein IIb/IIIa inhibitors in patients with myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of observational studies

Author

Kouz, Remi, primary, Kouz, Simon, additional, Schampaert, Erick, additional, Rinfret, Stephane, additional, Tardif, Jean-Claude, additional, Nguyen, Michel, additional, Eisenberg, Mark, additional, Harvey, Richard, additional, Afilalo, Marc, additional, Lauzon, Claude, additional, Dery, Jean-Pierre, additional, Mansour, Samer, additional, and Huynh, Thao, additional

Published
2011
Full Text
View/download PDF

56. CYTOCHROME P450 2C19*17 POLYMORPHISM OFFSETS THE NEGATIVE EFFECT OF 2C19*2 POLYMORPHISM ON PLATELET REACTIVITY IN PATIENTS TREATED WITH CLOPIDOGREL

Author

Dery, Jean-Pierre, primary, Tourigny, Erick, additional, Déry, Ugo, additional, Tizon-Marcos, Helena, additional, Bagur, Rodrigo, additional, Rodés-Cabau, Josep, additional, Larose, Eric, additional, Rinfret, Stephane, additional, Gleeton, Onil, additional, Proulx, Guy, additional, Barbeau, Gérald, additional, Noël, Bernard, additional, Roy, Louis, additional, De Larochellière, Robert, additional, Nguyen, Can Manh, additional, Bossé, Yohan, additional, Tricoci, Pierluigi, additional, and Becker, Richard C., additional

Published
2011
Full Text
View/download PDF

57. PREVALENCE AND IMPACT OF RENAL FAILURE IN OCTOGENARIANS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION

Author

Dery, Jean-Pierre, primary, Tizon-Marcos, Helena, additional, Bernard, Pierre-Louis, additional, Plaisance, Julie, additional, Boulanger-Gobeil, Cindy, additional, Rodés-Cabau, Josep, additional, Barbeau, Gerald, additional, Larose, Eric, additional, Rinfret, Stephane, additional, Nguyen, Can M., additional, Gleeton, Onil, additional, Proulx, Guy, additional, Noël, Bernard, additional, Roy, Louis, additional, Delarochellière, Robert, additional, and Bertrand, Olivier F., additional

Published
2010
Full Text
View/download PDF

58. PREDICTORS OF MORTALITY AND LONG-TERM OUTCOMES OF OCTOGENARIANS UNDERGOING TRANSRADIAL PERCUTANEOUS CORONARY INTERVENTION

Author

Dery, Jean-Pierre, primary, Tizon, Helena, additional, Boulanger-Gobeil, Cindy, additional, Plaisance, Julie, additional, Barbeau, Gerald, additional, Rodés-Cabau, Josep, additional, Rinfret, Stephane, additional, Larose, Eric, additional, Noël, Bernard, additional, Nguyen, Can M., additional, Gleeton, Onil, additional, Proulx, Guy, additional, Roy, Louis, additional, Delarochellière, Robert, additional, and Bertrand, Olivier F., additional

Published
2010
Full Text
View/download PDF

59. Abstract 911: Usefulness of Coronary Fractional Flow Reserve Measurements to Guide Clinical Decisions in Intermediate Left Main Coronary Stenoses. Results of a Study Including 142 Consecutive Patients

Author

Rodès-Cabau, Josep, primary, Courtis, Javier, additional, Potvin, Jean-Michel, additional, Côté, Melanie, additional, Dery, Jean-Pierre, additional, Larose, Eric, additional, Nguyen, Can M, additional, Gleeton, Onil, additional, Roy, Louis, additional, DeLarochellière, Robert, additional, and Bertrand, Olivier F, additional

Published
2008
Full Text
View/download PDF

60. Abstract 2025: TIMI Major Bleeding Independently Predicts Mortality in an Unselected STEMI Population: Results from the AMI-Quebec Study

Author

L’Allier, Philippe, primary, Huynh, Thao, additional, Schampaert, Erick, additional, Kouz, Simon, additional, Eisenberg, Mark, additional, Lauzon, Claude, additional, Afilalo, Marc, additional, de Larocheliere, Robert, additional, Nguyen, Michel, additional, Levesque, Claude, additional, Dery, Jean Pierre, additional, Rinfret, Stephane, additional, and Tardif, Jean Claude, additional

Published
2008
Full Text
View/download PDF

61. Abstract 2006: Contrast-Enhanced MRI in the Hyperacute Phase of ST-Elevation Myocardial Infarction Predicts Late Myocardial Recovery

Author

Larose, Eric, primary, Rodes, Josep, additional, Nguyen, Can, additional, Proulx, Guy, additional, Gleeton, Onil, additional, Dery, Jean-Pierre, additional, Noel, Bernard, additional, Barbeau, Gérald, additional, Roy, Louis, additional, Amyot, Marc, additional, Delarochellière, Robert, additional, and Bertrand, Olivier, additional

Published
2008
Full Text
View/download PDF

63. Optimal duration of eptifibatide infusion in percutaneous coronary intervention (An ESPRIT substudy)

Author

Rebeiz, Abdallah G., primary, Dery, Jean-Pierre, additional, Tsiatis, Anastasios A., additional, O'Shea, J. Conor, additional, Johnson, Brent A., additional, Hellkamp, Anne S., additional, Pieper, Karen S., additional, Gilchrist, Ian C., additional, Slater, James, additional, Muhlestein, J. Brent, additional, Joseph, Diane, additional, Kitt, Michael M., additional, and Tcheng, James E., additional

Published
2004
Full Text
View/download PDF

64. Final results of the ReoPro readministration registry

Author

Dery, Jean-Pierre, primary, Braden, Gregory A, additional, Lincoff, A.Michael, additional, Kereiakes, Dean J, additional, Browne, Kevin, additional, Little, Thomas, additional, George, Barry S, additional, Sane, David C, additional, Cines, Douglas B, additional, Effron, Mark B, additional, Mascelli, Mary Ann, additional, Langrall, Mary Ann, additional, Damaraju, Lakshmi, additional, Barnathan, Elliot S, additional, and Tcheng, James E, additional

Published
2004
Full Text
View/download PDF

65. Abciximab readministration: Final results of the reoprofireadministration registry

Author

Dery, Jean-Pierre, primary, Braden, Gregory A., additional, Michael Lincoff, A., additional, Kereiakes, Dean J., additional, Browne, Kevin F., additional, Little, Thomas, additional, George, Barry S., additional, Effron, Mark B., additional, Ann Mascelli, Mary, additional, Ann Langrall, Mary, additional, Damaraju, Lakshmi, additional, Barnathan, Elliot S., additional, and Tcheng, James E., additional

Published
2003
Full Text
View/download PDF

71. Effects of vorapaxar on platelet reactivity and biomarker expression in non-ST-elevation acute coronary syndromes

Author

Storey, Robert F., Kotha, Jayaprakash, Smyth, Susan S., Moliterno, David J., Rorick, Tyrus L., Moccetti, Tiziano, Valgimigli, Marco, Dery, Jean Pierre, Cornel, Jan H., Thomas, Gregory S., Huber, Kurt, Harrington, Robert A., Hord, Edward, Judge, Heather M., Chen, Edmond, Strony, John, Mahaffey, Kenneth W., Tricoci, Pierluigi, Becker, Richard C., and Jennings, Lisa K.

Published
2014
Full Text
View/download PDF

74. Clinical Characteristics Predict Benefits From Eptifibatide Therapy During Coronary Stenting Insights From the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) Trial

Author

Puma, Joseph A., Banko, Lesan T., Pieper, Karen S., Sacchi, Terrence J., O’Shea, J. Conor, Dery, Jean Pierre, and Tcheng, James E.

Abstract

ObjectivesIn order to determine a differential benefit from treatment, we compared the long-term outcome of high-risk versus low-risk patients and evaluated survival free from death or myocardial infarction at one year.BackgroundNewer anticoagulant strategies during percutaneous coronary intervention have necessitated a reanalysis of the role of intravenous GP IIb/IIIa inhibitors. The Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial randomized 2,064 patients undergoing nonurgent coronary stent implantation to eptifibatide or placebo.MethodsHigh-risk characteristics were defined as age >75 years, diabetes, elevated cardiac markers, ST-segment elevation myocardial infarction within 7 days, or unstable angina within 48 h of randomization. Age

Full Text
View/download PDF

75. TCT-241 Elective General Anesthesia for Patients Undergoing Complex and High-Risk Intervention in Indicated Patients (CHIP) Percutaneous Coronary Interventions.

Author

Pasos, Julio Farjat, Houle, Simon, Barbeau, Gerald, Poulin, Anthony, Beaupre, Frederic, Garcia-Labbe, David, Dery, Jean-Pierre, Cieza, Tomas, Larose, Eric, Noel, Bernard, Bertrand, Olivier, De Larochelliere, Robert, Rodes-Cabau, Josep, Rinfret, Stephane, Nguyen, Can, and Paradis, Jean-Michel

Subjects
*PERCUTANEOUS coronary intervention, *GENERAL anesthesia
Published
2024
Full Text
View/download PDF

76. Clinical Characteristics Predict Benefits From Eptifibatide Therapy During Coronary Stenting: Insights From the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) Trial

Author

Puma, Joseph A., Banko, Lesan T., Pieper, Karen S., Sacchi, Terrence J., O’Shea, J. Conor, Dery, Jean Pierre, and Tcheng, James E.

Subjects
*PLACEBOS, *MYOCARDIAL infarction, *CORONARY disease, *HEART diseases, *INFARCTION, *PERIPHERAL vascular diseases
Abstract

Objectives: In order to determine a differential benefit from treatment, we compared the long-term outcome of high-risk versus low-risk patients and evaluated survival free from death or myocardial infarction at one year. Background: Newer anticoagulant strategies during percutaneous coronary intervention have necessitated a reanalysis of the role of intravenous GP IIb/IIIa inhibitors. The Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy trial randomized 2,064 patients undergoing nonurgent coronary stent implantation to eptifibatide or placebo. Methods: High-risk characteristics were defined as age >75 years, diabetes, elevated cardiac markers, ST-segment elevation myocardial infarction within 7 days, or unstable angina within 48 h of randomization. Age <5 years, absence of diabetes, and any other reason for admission were considered low risk characterstics. Results: There were 1,018 patients in the high-risk group (50.8% eptifibatide, 49.2% placebo) and 1,045 patients in the low-risk group (50.0% eptifibatide, 50.0% placebo). Baseline demographics were similar in both groups except for more hypertension (63% vs. 55%, respectively), peripheral vascular disease (8.2% vs. 5.2%, respectively), prior stroke (5.5% vs. 3.2%, respectively), and female gender (33% vs. 22%, respectively) in the high-risk than the low-risk group. At one year, the composite end point of death or myocardial infarction occurred in 15.89% of placebo patients and 7.99% of eptifibatide patients in the high-risk group and 9.02% of the placebo and 8.11% of eptifibatide patients in the low-risk group. Conclusions: Although eptifibatide treatment improved outcomes for all patients, preprocedural clinical characteristics can define a subgroup of patients who may derive greatest benefit from its use during coronary stent placement. [Copyright &y& Elsevier]

Published
2006
Full Text
View/download PDF

77. Ten-Year Statin Adherence in Survivors of ST-Segment Elevation Myocardial Infarction.

Author

Huynh T, Lecca P, Montigny M, Gagnon R, Eisenberg MJ, Lauzon C, Mansour S, Rinfret S, Afilalo M, Nguyen M, Kouz S, Dery JP, Harvey R, Schampaert E, and Tardif JC

Subjects
Age Factors, Aged, Aged, 80 and over, Angiotensin Receptor Antagonists administration & dosage, Angiotensin-Converting Enzyme Inhibitors administration & dosage, Cohort Studies, Female, Follow-Up Studies, Hospitalization statistics & numerical data, Humans, Logistic Models, Male, Middle Aged, Multivariate Analysis, Percutaneous Coronary Intervention statistics & numerical data, Quebec, Survivors statistics & numerical data, Time Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Medication Adherence statistics & numerical data, ST Elevation Myocardial Infarction drug therapy
Abstract

Background          Adherence to statins is often sub-optimal and declines over time. Direct costs incurred by patients are frequently cited as responsible for inadequate statin adherence. To determine whether survivors of ST-segment elevation myocardial infarction (STEMI), who benefit from low or no cost drug dispensation, have optimal long-term adherence to statins, we aimed to evaluate the ten-year adherence to statin of these patients. Methods          The AMI-QUEBEC Study follows a cohort of STEMI survivors hospitalized at 17 hospitals in Quebec, Canada during the year 2003. We obtained their 10-year data on lipid lowering therapy (LLT) consumption. Optimal adherence was defined as the proportion of days covered of ≥80%. We used multivariate logistic regression to determine factors independently associated with optimal adherence to statins. Results          Complete 10-year data on statin dispensation was available for 524 patients. Optimal adherence remained stable over time at 80% and more during the 10-year follow-up period. During the last five years, 12% of patients did not use any LLT. Older age, living in less socially deprived areas, concomitant use of angiotensin-converting-enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB), and admission to hospitals with percutaneous coronary interventions facilities (PCI-hospitals) were associated with improved statin adherence.   Conclusion Future studies are needed to explore the potential factors associated with concomitant use of ACEI/ARB, and admission to PCI-hospitals that may have optimized statin adherence. Socially deprived patients may benefit from more support and encouragement to enhance their long-term statin adherence.

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results